EGFR and neoplasm: In terms of tumor response, progression-free survival (PFS), and overall survival (OS), anti-EGFR monoclonal antibody with chemotherapy is the most effective treatment for patients with metastatic colorectal cancer (mCRC) whose primary tumor is situated in the left colon or rectum.